Next US FDA Generics Leader Must Have ‘Frank Conversations’ With Colleagues, Industry, Former OGD Director Says
Susan Rosencrance, who helped negotiate GDUFA III, will take over as acting director of the Office of Generic Drugs following Sally Choe’s departure on 8 October. Former OGD head Uhl says the director needs to be the ‘number one advocate for the generic drug program inside the agency.’
You may also be interested in...
US FDA Opens OTP Director Search Again
The new job notice offers a top salary, but also invites questions about the candidate pool attracted by the original solicitation.
The Risk-Reward Of US FDA Leadership Running Offices Below Them
CBER’s Celia Witten is the latest senior executive to run an office within the center during a leadership transition, a move that can help achieve specific goals, but also create tension.
US FDA Wants More Generic-Specific Experience In Next OGD Director
Vacancy notice includes preferences for candidates with experience formulating generic drug policy and strategy, as well as in overall drug development, which is intended to make the search more efficient.